Coherus BioSciences Inc expected to post a loss of 12 cents a share - Earnings Preview

Coherus Oncology

11/03/2024 20:03

* Coherus BioSciences Inc  CHRS.OQ   CHRS.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 13
for the period ending December 31 2023
    * The Redwood City California-based  company is expected to
report
a 112.6% increase in revenue to $96.4 million from $45.35
million a year ago, according to the mean estimate from 10
analysts, based on LSEG data.The company's guidance on November
6 2023, for the period ended December 31, was for revenue
between $85.00 million and $95.00 million.
    * ​LSEG's mean analyst estimate for Coherus BioSciences Inc
is for
a loss of 12 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Coherus
BioSciences Inc is $9.00​, above​ its last closing price
of $2.39. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.29       -0.27      -0.27     Met     1.7
 Jun. 30 2023  -0.48       -0.48      -0.38     Beat    21.6
 Mar. 31 2023  -0.54       -0.57      -0.75     Missed  -31​
 Dec. 31 2022  -0.87       -0.84      -0.60     Beat    28.4
 ​​Sep.        -0.56       -0.57      -0.96     Missed  -68.4
 30 2022                                                
 Jun. 30 2022  -0.64       -0.64      -0.47     Beat    26.6​
 Mar. 31 2022  -0.49       -0.48      -1.00     Missed  -107.3
 Dec. 31 2021  -0.37       -0.51      -0.46     Beat    10.2
 This summary was machine generated March 11 at 20:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)